Tags

Type your tag names separated by a space and hit enter

Microbicides for prevention of HIV infection: clinical efficacy trials.
Curr Top Microbiol Immunol. 2014; 383:97-115.CT

Abstract

Microbicides are an important HIV prevention technology under development, but the clinical testing of candidate products for efficacy faces many design and ethical challenges. Nevertheless, several microbicide candidates have been tested or are under development. Eight candidate products have entered late stage microbicide effectiveness trials. Following 11 disappointing effectiveness trial results of six candidate products over the past 20 years, substantial progress is now being made in microbicide development following the release of the CAPRISA 004 tenofovir gel trial results in 2010, which provided proof of concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. A trial is currently underway to confirm the effectiveness of tenofovir gel and two others have recently been initiated to assess ring formulations of the antiretroviral drug, dapivirine.

Authors+Show Affiliations

Nelson R Mandela School of Medicine, CAPRISA-Centre of AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Private Bag X7, Congella, Durban, 4013, South Africa , karims1@ukzn.ac.za.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23695725

Citation

Abdool Karim, Salim S., and Cheryl Baxter. "Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials." Current Topics in Microbiology and Immunology, vol. 383, 2014, pp. 97-115.
Abdool Karim SS, Baxter C. Microbicides for prevention of HIV infection: clinical efficacy trials. Curr Top Microbiol Immunol. 2014;383:97-115.
Abdool Karim, S. S., & Baxter, C. (2014). Microbicides for prevention of HIV infection: clinical efficacy trials. Current Topics in Microbiology and Immunology, 383, 97-115. https://doi.org/10.1007/82_2013_330
Abdool Karim SS, Baxter C. Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. Curr Top Microbiol Immunol. 2014;383:97-115. PubMed PMID: 23695725.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Microbicides for prevention of HIV infection: clinical efficacy trials. AU - Abdool Karim,Salim S, AU - Baxter,Cheryl, PY - 2013/5/23/entrez PY - 2013/5/23/pubmed PY - 2015/3/4/medline SP - 97 EP - 115 JF - Current topics in microbiology and immunology JO - Curr Top Microbiol Immunol VL - 383 N2 - Microbicides are an important HIV prevention technology under development, but the clinical testing of candidate products for efficacy faces many design and ethical challenges. Nevertheless, several microbicide candidates have been tested or are under development. Eight candidate products have entered late stage microbicide effectiveness trials. Following 11 disappointing effectiveness trial results of six candidate products over the past 20 years, substantial progress is now being made in microbicide development following the release of the CAPRISA 004 tenofovir gel trial results in 2010, which provided proof of concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. A trial is currently underway to confirm the effectiveness of tenofovir gel and two others have recently been initiated to assess ring formulations of the antiretroviral drug, dapivirine. SN - 0070-217X UR - https://www.unboundmedicine.com/medline/citation/23695725/Microbicides_for_prevention_of_HIV_infection:_clinical_efficacy_trials_ L2 - https://doi.org/10.1007/82_2013_330 DB - PRIME DP - Unbound Medicine ER -